MedTrace Logo

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04612751 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2026-04-06

No results posted yet for this study

Summary

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Advanced or Metastatic NSCLC

Interventions

DRUG

Datopotamab deruxtecan

Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

DRUG

Durvalumab

Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

DRUG

Carboplatin

Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

DRUG

AZD2936

Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

DRUG

MEDI5752

Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

DRUG

AZD7789

Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2026-05-04
Completion
2026-05-04
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Italy
  • Japan
  • Poland
  • Spain
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04612751 on ClinicalTrials.gov